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Human herpesvirus 6 (HHV-6) is a potentially immunosuppressive CD4-T-lymphotropic betaherpesvirus
that causes severe human thymocyte depletion in heterochimeric SCID-hu thy/livmice and has been implicated
as a potential cofactor in the progression of AIDS. However, the mechanisms of HHV-6-mediated immuno-
suppression have not yet been fully elucidated. We investigated the phenotypic and functional alterations
induced by HHV-6 on peripheral blood-derived human dendritic cells (DC). The infection of DC with HHV-6
A or B was nonproductive, as revealed by calibrated real-time PCR measuring the accumulation of viral ge-
nome equivalents over time. Nevertheless, preexposure to HHV-6 markedly impaired the maturation of DC
driven by gamma interferon and lipopolysaccharide, as shown by the reduced surface expression of major
histocompatibility complex class I molecules, HLA-DR, CD40, and CD80. Moreover, HHV-6, but not the closely
related betaherpesvirus HHV-7, dramatically suppressed the secretion of interleukin-12 (IL-12) p70 by DC,
while the production of other cytokines that influence DC maturation, i.e., IL-10 and tumor necrosis factor
alpha, was not significantly modified. Likewise, the secretion of the CC chemokines macrophage inflammatory
protein 1 and RANTES was unaltered. Functionally, a pretreatment with HHV-6 impaired the ability of DC
to stimulate allogeneic T-cell proliferation. Altogether, these data identify interference with the functional
maturation of DC as a potential mechanism of HHV-6-mediated immunosuppression.
Immune responses against invading microorganisms can be
broadly divided into two major compartments, innate immu-
nity and adaptive immunity, which differ markedly with regard
to the mechanisms and specificities of molecular target recog-
nition but also show areas of overlap in terms of regulatory
cells and effector pathways. In this respect, a paradigmatic
example is represented by dendritic cells (DC), which respond
to pathogen-associated molecular patterns but also act as pro-
fessional antigen-presenting cells (APC) for the antigen-spe-
cific activation of B and T lymphocytes (4). DC play a pivotal
role in the orchestration of immune responses. They are in-
volved in T-lymphocyte activation after antigen encounters and
contribute to the polarization of immune responses towards
the most suitable cytokine secretion phenotype (i.e., Th1 or
Th2) for the control of specific microorganisms (4). The pro-
duction of defined cytokines and the modulation of DC mem-
brane markers are required for the development of such po-
larized responses. Modulation of the expression of several DC
surface molecules (e.g., CD40, CD80, CD86, LFA-1, and ma-
jor histocompatibility complex [MHC] class I and II molecules)
influences the efficiency of subsequent T-cell responses; as for
soluble factors, a critical element in the generation of effective
antiviral immune responses is interleukin-12 (IL-12), a cyto-
kine that drives the polarization of T lymphocytes towards a
Th1 cytokine secretion pattern (12). In fact, Th1 cells, charac-
terized by the selective production of gamma interferon
(IFN-) and IL-2, play an important role in the generation of
cytotoxic T lymphocytes, which effectively counteract intracel-
lular microorganisms, including viruses. The essential role
played by DC in the generation of effective immune responses
makes them attractive targets for microbial strategies aimed at
dysregulating host immune defenses. Thus, several viruses, in-
cluding human herpesviruses (HHVs), have developed effec-
tive strategies for evading and subverting immune responses,
which include targeting DC functions through the impairment
of their maturation and cytokine production (1).
HHV-6, originally isolated from patients with lymphoprolif-
erative diseases and immunosuppression (24), is classified
within the Betaherpetovirinae subfamily, along with Human cy-
tomegalovirus and HHV-7. HHV-6 is further classified into two
variants, A and B, which show significant genetic, immunolog-
ical, and biological divergence. HHV-6 B has been identified as
the etiologic agent of exanthem subitum in infants (30), but the
pathogenic role of HHV-6 A remains uncertain. Like other
herpesviruses, HHV-6 is able to induce latent infections and
may persist indefinitely in the host. In immunocompromised
patients, HHV-6 reactivation or reinfection may cause severe
opportunistic diseases, including encephalitis, pneumonitis,
hepatitis, and retinitis, as well as bone marrow graft failure (8).
Multiple lines of clinical and experimental evidence suggest
that HHV-6 may act as an immunosuppressive agent. In SCID-
hu thy/liv mice engrafted with human thymic tissue, infection
with either HHV-6 A or B results in vigorous virus replication
and rapid destruction of the graft, with thymocyte depletion
affecting all major intrathymic cell populations (11). Consistent
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with these experimental observations, sporadic cases of fatal
immunosuppression associated with disseminated HHV-6 in-
fection have been reported (16, 31). Moreover, for allogeneic
stem cell transplant recipients, defective antigen-specific T-
lymphocyte proliferation was documented during episodes of
HHV-6 reactivation or reinfection (29). The mechanisms that
underlie HHV-6-induced immunosuppression are still largely
unknown. In vitro, HHV-6 shows a preferential tropism for
CD4 T cells, in which it replicates most effectively and in-
duces strong cytopathic effects (20). One important mechanism
of HHV-6 pathogenesis is the engagement of the primary viral
receptor, CD46 (25), a complement-regulatory cell surface
molecule that provides a key link between innate and adaptive
immune responses. Recently, we have shown that exposure to
HHV-6 results in a dramatic inhibition of IL-12 p70 produc-
tion by differentiated human macrophages in the absence of a
productive viral infection (27), a phenomenon that is likely
mediated by CD46 engagement. Other mechanisms of immune
dysregulation by HHV-6 include defective antigen presenta-
tion by DC (13) and aberrant cytokine production by periph-
eral blood mononuclear cells, such as an increased secretion of
IL-1, tumor necrosis factor alpha (TNF-), and IL-10 (2, 9)
and a decreased secretion of IL-2 associated with diminished
cellular proliferation (10).
For the present study, we investigated the effects of HHV-6
on the maturation and function of DC, which were studied as
a model of professional APC. Although HHV-6 was unable to
actively replicate in these cells, it prevented their full matura-
tion and caused a dramatic and selective blockade of IL-12 p70
secretion. Such defects had a functional correlate, as HHV-6-
treated DC showed a reduced ability to stimulate allogeneic
T-cell proliferation. These data illustrate a novel mechanism of
HHV-6-mediated immunosuppression.
MATERIALS AND METHODS
DC purification and differentiation. Peripheral blood mononuclear cells were
generated by Ficoll-Paque gradient purification (Pharmacia Biotech AB, Upp-
sala, Sweden) from concentrated white blood cells of healthy blood donors. The
lymphocyte-rich layer was harvested and washed three times with cold phos-
phate-buffered saline (PBS). After the final wash, the cell pellet was resuspended
in 20 ml of isosmotic RPMI containing 10% fetal calf serum (Bio-Whittaker
Europe, Verviers, Belgium). Five milliliters of the cell solution was layered over
5 ml of a 46% Percoll solution in a 15-ml polystyrene tube (Pharmacia Biotech
AB). The Percoll gradients were spun at 550 g for 30 min at 4°C with the brake
turned off. The monocyte layer was harvested and washed three times with cold
PBS. After the last wash, the cells were resuspended in complete Dulbecco’s
modified Eagle’s medium, counted, and diluted to 0.5  106 cells/ml with Dul-
becco’s modified Eagle’s medium. Cells (1  106 to 3  106) were plated in
six-well polystyrene plates for 1 h at 37°C to allow for adherence. After 1 h, the
plates were washed three times with warm PBS to remove nonadherent cells.
Finally, 2 ml of complete RPMI containing 500 U of IL-4/ml and 50 ng of
granulocyte-macrophage colony-stimulating factor (Pharmacia Biotech AB)/ml
was added to each well. Every 2 to 3 days for 5 to 7 days, 1 ml of medium was
replaced with fresh medium and cytokines. At the end of the differentiation
period, the cells were harvested and the DC phenotype was confirmed by fluoroc-
ytometric analysis. Altogether, residual contamination by non-DC (i.e., CD14
mononuclear phagocytes, CD3 T cells, CD19 B cells, or CD56 NK cells) was
consistently lower than 5%.
For DC differentiation, the cells were treated first with 500 U of IFN-
(CABRU SAS, Milan, Italy)/ml for 17 h and then with 1 g of lipopolysaccharide
(LPS; Sigma, St. Louis, Mo.)/ml for 24 h. Cell-free culture supernatants were
then harvested for the measurement of cytokines and chemokines by enzyme-
linked immunosorbent assays (ELISAs), whereas the cells were used for fluoro-
cytometric analyses of surface marker expression.
Viral stocks and inactivation with UV light. The viral strains used for this study
were HHV-6 A strain GS (24) and HHV-B strain PL-1 (11). Viral stocks were
generated by expansion in cord blood mononuclear cells (CBMC) that had been
previously activated for 3 days with 5 g of phytohemagglutinin (PHA; Sigma)/
ml. Briefly, 5  106 activated CBMC were pelleted in a 50-ml polystyrene tube
at 300 g for 10 min. The cells were infected at a multiplicity of infection (MOI)
of about 0.2 (i.e., 2 infectious units per 10 cells) for 2 to 4 h at 37°C. The cultures
were then diluted to 106 cells/ml with RPMI containing 10% fetal calf serum and
were incubated for 7 days. Culture supernatants were collected on day 7 or when
the majority of the cells showed morphological signs of infection. Infectious
supernatants were clarified by spinning at 300  g for 10 min and then stored at
80°C until use. For HHV-6 inactivation by UV light, infectious supernatants
were exposed to UV light for 5 min at a distance from the source of 20 cm and
then kept on ice until use. HHV-7 infectious supernatants (strain AL) (26) were
produced by CD8-depleted, PHA-activated CBMC under similar conditions as
those used to grow HHV-6, with the exception that recombinant human IL-2
(Chiron, Amsterdam, The Netherlands) was added at 10 U/ml. All reagents,
including viral supernatants, were tested for endotoxin contamination by the use
of the Pyrogen Plus detection kit (BioWhittaker) with a lower detection limit of
0.125 EU/ml.
Virion enrichment by ultracentrifugation and infection of DC with HHV-6 or
HHV-7. An HHV-6 (A or B) or HHV-7 infectious supernatant was layered over
a 20% sucrose cushion and spun at 36,000  g for 1 h in a type 50 Ti rotor in an
L-80 ultracentrifuge (Beckman Instruments, Inc., Palo Alto, Calif.). The pellet
was then resuspended in complete RPMI to generate a 23 concentrated stock
of each virus.
For infections, DC were plated at 106 cells/ml in 12-well polystyrene plates in
complete RPMI containing 500 U of IL-4/ml and 50 ng of granulocyte-macro-
phage colony-stimulating factor/ml. Ultracentrifugation-purified HHV-6 and HHV-
7 were diluted 23 times in complete medium and added to the cultures at an ap-
proximate MOI of 1. The cells were cultured in the presence of virus for 17 h,
after which they were washed and induced to mature by the use of IFN- and LPS.
Quantification of HHV-6 DNA by real-time PCR. HHV-6 replication, mea-
sured as the accumulation of intracellular viral genome equivalents over time, was
assessed by quantitative PCR for HHV-6 DNA, which was based on TaqMan tech-
nology using an ABI PRISM 7700 sequence detector as previously described (19).
Fluorocytometry. Fluorocytometric analysis was used to study the expression
of selected cell surface markers. For each antibody, 1  105 to 5  105 cells were
used in 5-ml polystyrene round-bottomed tubes (Becton Dickinson Labware,
Franklin Lanes, N.J.). The cells were washed with cold PBS supplemented with
2% human serum at 250  g for 5 min and then incubated for 30 min on ice with
primary antibodies. The primary antibodies used were anti-CD40, -CD80, and
-CD86 (Serotec, Oxford, England) and anti-MHC class I (clone W6/32) and
-HLA-DR (clone L243) (a kind gift of Lorenzo Piemonti). After two additional
washes with PBS plus 2% human serum, the cells were incubated for an addi-
tional 30 min with the appropriate secondary antibody conjugated to either
fluorescein isothiocyanate or phycoerythrin (Sigma). The cells were then further
washed with PBS plus 2% human serum by centrifugation at 250  g for 5 min.
Both infected and uninfected cells were fixed with PBS containing 3% formal-
dehyde before analysis. Fluorocytometric analysis was performed by use of a
FACScan analyzer (Becton Dickinson, San Jose, Calif.). Appropriate gating was
used to exclude dead cells, and at least 10,000 events were acquired for each sample.
Measurement of cytokine and chemokine release. The levels of cytokines and
chemokines (IL-12 p70, TNF-, IL-10, RANTES, and macrophage inflammatory
protein 1 [MIP-1]) released into the culture supernatants were measured by
ELISAs (R&D Systems, Minneapolis, Minn.) performed according to the man-
ufacturer’s instructions. The IL-12 ELISA was reported to have no cross-reac-
tivity or interference with IL-12 p40 or IL-12 p35 monomers or homodimers.
ELISA results were normalized for cell numbers and then used to calculate
means with appropriate standard deviations (SD) for multiple donors. P values
were calculated by the two-tailed paired t test. For data derived from two donors,
ELISA results were used to calculate mean values with appropriate standard
errors (SE).
Allogeneic T-lymphocyte proliferation assay. Enriched T-cell preparations
were obtained as follows. Peripheral blood mononuclear cells from healthy blood
donors were obtained from buffy coats by standard gradient separation proce-
dures. The cells (5  106) were washed in RPMI and incubated in complete
medium containing 0.5% carbonyl iron (Sigma) for 60 min at 37°C on a rotating
wheel; phagocytic cells were then removed with a magnet as previously described
(5). After this procedure, residual monocytes accounted for 1% of the cell
population, as confirmed by fluorocytometry with an anti-CD14 monoclonal
antibody. For mixed leukocyte reactions, DC were pretreated with UV-inacti-
vated HHV-6 A at an approximate MOI of 1 or with uninfected culture medium
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overnight and then either left immature or matured with IFN- and LPS as
described above. Different numbers of DC were then cocultured for 5 days at
different ratios in 96-well flat-bottomed plates (Nunc) together with 105 heter-
ologous lymphocytes/well; DC-to-lymphocyte ratios ranged from 1:5 to 1:100.
Allogeneic T-lymphocyte proliferation was evaluated by measuring the incorpo-
ration of [methyl-3H]thymidine (0.8 Ci/well; Amersham Biosciences, Freiburg,
Germany), which was added to the cultures during the last 6 h before harvesting.
The cells were then harvested, and radioactivity was measured with a Wallac
LKB counter (Perkin-Elmer, Shelton, Colo.).
RESULTS
Lack of HHV-6 replication in DC. To investigate the effects
of HHV-6 on DC, we initially evaluated the ability of viral
strains representing the two major viral variants, A and B, to
replicate in human peripheral blood-derived DC. PHA-acti-
vated human CBMC were tested in parallel as a control. Figure
1 shows that the exposure of immature DC to HHV-6 A (strain
GS) did not result in the accumulation of viral genome
equivalents over time, as evaluated by a quantitative cali-
brated real-time PCR assay; likewise, no other signs of pro-
ductive infection, such as cytomorphological changes, loss of
cellular viability, or expression of the nuclear phosphoprotein
pp41, an early-late viral antigen, were detected throughout the
observation period (not shown). In contrast, the same HHV-6
stock initiated vigorous viral replication in CBMC, as revealed
by the progressive accumulation of HHV-6 genomes over time
(Fig. 1). Similar results (not shown) were obtained for HHV-6
B (strain PL-1).
Effect of HHV-6 on the expression of DC membrane differ-
entiation markers. Next, we investigated the effects of HHV-6
on the maturation of human DC, as assessed by changes in the
expression of selected surface markers that are modulated
during DC maturation. As shown in Fig. 2A, pretreatment with
HHV-6 A (strain GS) had little effect on immature DC ex-
pression of CD40 and CD80, while there were slight changes in
the expression of MHC class I (upregulated) and HLA-DR
(downregulated). In contrast, in DC differentiated by IFN-
and LPS, pretreatment with HHV-6 markedly reduced the
upregulation of all of the differentiation markers examined
(Fig. 2B). Similar data (not shown) were obtained with DC
treated with HHV-6 B.
HHV-6 inhibits the production of IL-12 by human DC. As
illustrated in Fig. 3, unstimulated DC failed to produce signif-
icant levels of IL-12 p70, regardless of the pretreatment with
HHV-6; in contrast, stimulation with IFN- and LPS induced
a vigorous production of IL-12 p70, but such production was
dramatically suppressed by pretreatment with either HHV-6 A
(panel A) or HHV-6 B (panel B). A dose-dependent IL-12
inhibition effect was seen with serial dilutions of the viral stocks
(not shown). Notably, UV light inactivation of the viral stocks
did not eliminate the suppressive activity (	90% reduction of
FIG. 1. Lack of productive HHV-6 infection in DC. DC or PHA-
activated CBMC were infected with purified HHV-6 A virions at an
approximate MOI of 1. After 1, 3, and 6 days, the cells were harvested
and analyzed for viral DNA content by use of a quantitative calibrated
real-time PCR assay. Human -actin DNA was measured in parallel to
normalize the cell numbers. The data shown are from two represen-
tative DC donors and one CBMC donor and are expressed as HHV-6
genome equivalents per cell.
FIG. 2. Inhibition of IFN-- and LPS-induced DC maturation by HHV-6. DC were preexposed to purified HHV-6 A virions and then cultured
for 40 h in the absence (A) or presence (B) of IFN- and LPS. The cells were then harvested and analyzed for surface expression of CD40, MHC
classes I and II, and CD80 by fluorocytometry. Profiles of HHV-6-treated DC are shown as black lines, while those of uninfected controls are shown
as gray lines. The number on each line denotes the mean fluorescence intensity value. Representative data from one of three donors tested are shown.
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IL-12 release with UV-treated virus), thus formally proving
that the HHV-6-induced inhibition of IL-12 p70 in DC is
independent of virus replication. These results demonstrated
that preexposure to HHV-6 A or B profoundly affects the
capacity of human DC to produce IL-12 p70.
HHV-6 does not significantly influence the production of
other cytokines and chemokines by DC. HHV-6 infection has
been reported to cause an increased production of IL-10 and
TNF- (2), two cytokines that can modulate DC maturation (4,
7). Thus, we tested the possibility that the HHV-6-mediated
inhibition of DC maturation was related to the autocrine pro-
duction of these cytokines. Only a limited, statistically nonsig-
nificant, increase in the production of IL-10 was detected in
supernatants of HHV-6-treated DC stimulated with IFN- and
LPS (Fig. 4A), while the release of TNF- was slightly de-
creased, but again the difference did not reach statistical sig-
nificance (Fig. 4B). These results suggest that the dramatic
effects induced by HHV-6 on DC maturation and IL-12 pro-
duction cannot be primarily ascribed to changes in the levels of
IL-10 and TNF-, even though in the case of IL-10 it cannot be
excluded that the levels of cytokine production had already
reached plateau levels upon IFN- and LPS stimulation.
We also evaluated whether the levels of other soluble factors
produced by DC could be influenced by pretreatment with
HHV-6. Figure 4C and D show that the production of the CC
chemokines MIP-1 and RANTES upon IFN- and LPS stim-
ulation was not affected by HHV-6 A; likewise, there was no
change in the spontaneous release of such chemokines by im-
mature DC. These data indicated that the suppression of IL-12
p70 by HHV-6 is selective and does not result from a gener-
alized functional impairment of DC.
Lack of IL-12 p70 inhibition by HHV-7. Since a down-mod-
ulation of IL-12 production has also been reported for Human
cytomegalovirus, another member of the Betaherpetovirinae
subfamily (22), we evaluated whether this observation could be
extended to the third known human -herpesvirus, HHV-7. As
seen with HHV-6, no productive HHV-7 infection of DC was
documented by morphological observations and fluorocytom-
etry (data not shown). Figure 5 shows that pretreatment of
IFN-- and LPS-stimulated DC with concentrated HHV-7 viri-
ons at the same MOI as that used for HHV-6 failed to inhibit
the production of IL-12 p70. Also, the pretreatment of DC
with HHV-7 did not induce the production of IL-12 p70 by
unstimulated DC. These data suggest that the inhibition of
IL-12 p70 is not a general characteristic of all betaherpesvi-
ruses.
Inhibition of DC-induced allogeneic T-lymphocyte stimula-
tion by HHV-6. To investigate the functional relevance of the
DC maturation and cytokine secretion defects observed after
HHV-6 treatment, we assessed the effect of HHV-6 on the
ability of DC to stimulate the proliferation of allogeneic T
cells. Considering the remarkable susceptibility of T cells to a
productive HHV-6 infection, at variance with a previous study
(13), we used a UV light-inactivated virus in order to exclude
a loss of function related to virus-induced cytopathic effects
and cell death. As shown in Fig. 6, uninfected immature DC
weakly stimulated the proliferation of allogeneic T cells (panel
A), whereas, as expected, T-lymphocyte proliferation was
strongly enhanced when DC were previously differentiated
with IFN- and LPS (panel B). However, pretreatment with
HHV-6 caused a marked reduction in the proliferation of T
cells stimulated by either immature or mature DC (Fig. 6). In
contrast, in agreement with the IL-12 production results (Fig.
5), no reduction in allogeneic T-cell proliferation was seen
upon the exposure of DC to HHV-7 (data not shown).
DISCUSSION
The observation that several viruses have evolved strategies
to suppress DC functions provides strong in vivo support for
the concept that DC play a central role in the development of
effective antiviral immune responses (1). In this report, we
evaluated the effects of HHV-6, a potentially immunosuppres-
sive betaherpesvirus, in a well-established in vitro model that
mimics the functional maturation of DC. We observed a com-
plex pattern of interference with DC functions by both HHV-6
A and B. Pretreatment with HHV-6 impaired the ability of DC
to fully differentiate in response to IFN- and LPS treatment,
as demonstrated by a reduced expression of maturation-asso-
ciated surface markers. Moreover, the production of IL-12
FIG. 3. Inhibition of IL-12 p70 production from primary human
DC by HHV-6. Human peripheral blood-derived DC were preexposed
to purified HHV-6 virions and then stimulated with IFN- plus LPS or
left unstimulated. Control DC were not preexposed to HHV-6. Cul-
ture supernatants were analyzed for IL-12 p70 levels by ELISA 24 h
after the addition of LPS. (A) Mean results (
 SD) for DC from four
donors that were pretreated with HHV-6 subgroup A (strain GS).
(B) Mean results (
 SE) for DC from two donors that were pretreated
with HHV-6 subgroup B (strain PL-1).
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p70, a critical cytokine for Th1 polarization, was dramatically
and selectively inhibited. It is important to emphasize that we
were unable to document productive HHV-6 infections in our
DC cultures, in evident contrast with the results of a previous
study in which DC cultures were shown to effectively sustain
HHV-6 replication, as revealed by the expression of late viral
antigens (13). The reasons for these discrepancies are unclear
at present. The observation of late viral antigen expression in
the latter study may have been related to the different culture
conditions used or, alternatively, to residual T-cell contamina-
tion of DC cultures. Notably, such prominent expression of
late viral antigens was not accompanied by any signs of cyto-
pathic effects or loss of DC viability (13), reinforcing the con-
cept that a large proportion of the DC population in these
experiments was indeed spared from the full expression of the
viral lytic cycle.
As suggested by our previous results with differentiated hu-
man macrophages (27) as well as by studies of measles virus
(14), the dramatic effects of HHV-6 on DC maturation and
IL-12 secretion in the absence of detectable viral replication
most likely resulted from the engagement of the primary HHV-
6 receptor molecule, CD46 (25). Our results with a UV light-
inactivated virus, which is unable to replicate but maintains the
ability to engage the cell surface receptor, corroborate this
hypothesis. CD46 serves as a regulator of complement activa-
tion, protecting cells from autologous complement-mediated
damage; due to this critical physiological function, it is ex-
pressed at high levels on the surfaces of virtually all human
cells, including DC. Moreover, CD46 provides a key link be-
tween innate and adaptive immune responses (18, 21). Indeed,
CD46-mediated signaling was shown to induce downstream
effects that significantly modulate various immune functions,
including T-cell costimulation (3) and polarization toward a
T-regulatory cell phenotype (15) as well as the recruitment of
SHP-1 and increased nitric oxide production in macrophages
(17). These observations illustrate the complexity of CD46-
mediated signaling, which is further complicated by the diver-
sity in CD46 isoform-specific tyrosine phosphorylation (21).
While the precise CD46 signaling pathway induced by HHV-6
binding to human DC remains to be defined, our results are
compatible with a role of viral envelope-mediated CD46 en-
FIG. 4. Failure of HHV-6 to modulate IL-10, TNF-, MIP-1, and RANTES production from activated DC. Culture supernatants of DC that
had been preexposed to purified HHV-6 A virions and then either left unstimulated or stimulated with IFN- and LPS were tested for IL-10 (A),
TNF- (B), MIP-1 (C), and RANTES (D) levels by ELISAs. Mean results (
 SD) for five donors are shown in panels A to C, and mean results
for three donors are presented in panel D.
FIG. 5. Failure of HHV-7 to inhibit IL-12 p70 production from
primary human DC. Human peripheral blood-derived DC were pre-
exposed to purified HHV-7 virions at an approximate MOI of 1 and
then stimulated with IFN- plus LPS or left unstimulated. Control DC
were not preexposed to HHV-7. Culture supernatants were analyzed
for IL-12 p70 levels by ELISA 24 h after the addition of LPS. Mean
results (
 SE) for DC from two donors are shown.
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gagement in the selective functional impairment of HHV-6-
exposed DC, which occurs in the absence of detectable viral
replication.
A critical question that we tried to answer is the functional
relevance of the DC defects induced by exposure to HHV-6.
For this purpose, we measured the antigen-presenting capabil-
ity of HHV-6-treated DC in allogeneic T-cell proliferation
assays, demonstrating a markedly reduced ability to stimulate
T-lymphocyte responses. Note that we employed UV-inacti-
vated HHV-6 stocks in order to rule out potential cytopathic
effects related to viral replication in T cells. Diverse mecha-
nisms may underlie such an effect. Allogeneic T-cell responses
are affected by a complex array of membrane-bound and sol-
uble factors related to DC differentiation. Among the former,
the level of expression of major histocompatibility antigens and
costimulatory molecules may have a significant impact on the
efficiency of T-cell activation. Among the soluble factors se-
creted by DC upon stimulation, IL-12 plays a crucial role (23).
We have documented an effect of HHV-6 on the expression of
both membrane molecules (MHC classes I and II, CD40, and
CD80) and soluble factors (IL-12), which may cooperatively
account for the reduced T-cell stimulatory activity. Neverthe-
less, a role of other, still undefined mechanisms cannot be
excluded at present.
Even though the molecular mechanisms underlying the im-
paired DC maturation after contact with HHV-6 are still in-
completely understood, the present study raises specific issues
that pave the way for future investigations. First, HHV-6 treat-
ment induced a trend towards a reduction of TNF- and an
enhancement of IL-10 production, which in combination may
contribute, at least in part, to diminishing IL-12 production.
Second, the production of other soluble factors released upon
DC activation, such as RANTES and MIP-1, was not nega-
tively affected by HHV-6. Third, the immunomodulatory ef-
fects of HHV-6 are not common to all members of the Beta-
herpetovirinae subfamily, since they were not reproduced by the
closely related betaherpesvirus HHV-7. It is noteworthy that
HHV-7 does not use CD46 as a cellular receptor. Thus, our
results suggest that IL-12 p70 suppression is a specific effect
that is not derived from a generalized abatement of DC func-
tions; on the other hand, the overall strategy of HHV-6 is
emerging as a coordinated activity of multiple mechanisms
focused on the impairment of DC maturation and function.
Several lines of evidence suggest that HHV-6 may act as an
immunosuppressive agent (8, 20). However, the clinical obser-
vations are still limited, and the potential mechanisms of this
immunosuppressive activity are still largely unknown. One im-
plication of the dramatic IL-12 suppression observed herein is
the concept that HHV-6 may cause immunosuppression by
blocking Th1-polarized immune responses. To provide addi-
tional support for these in vitro observations, we will need to
verify them in vivo by testing the maturation and IL-12-pro-
ducing ability of DC isolated from patients with active HHV-6
infections. The observed functional impairment of DC is also
consistent with the notion that HHV-6 may act as a cofactor
during the course of human immunodeficiency virus type 1
(HIV-1) infection, accelerating the progression toward full-
blown AIDS (20). In this respect, it is noteworthy that periph-
eral blood mononuclear cells from patients infected with
HIV-1 were shown to produce lower levels of IL-12 upon in
vitro stimulation with Staphylococcus proteins than did unin-
fected controls (6). Studies on the status of HHV-6 infection
will be important to elucidate the role played by this herpes-
virus in the IL-12 downmodulation documented for HIV-in-
fected patients.
In conclusion, we have shown that HHV-6 prevents the
full maturation of human DC in the absence of viral repli-
cation and cytopathic effects, illustrating a novel mechanism
for HHV-6-mediated immunosuppression. Interestingly, an-
other virus that uses CD46 as a cellular receptor, i.e., measles
virus, is also associated with immunosuppression (14). Unfor-
tunately, formal proof of the role of CD46 binding in the
observed DC effects is difficult to achieve due to the fact that
the anti-CD46 antibodies that may be used to block the HHV-
6–CD46 interaction are themselves functionally active and suf-
ficient to affect APC maturation and function (14, 27). In
FIG. 6. Reduced proliferation of T cells by allogeneic DC pre-
treated with HHV-6. Peripheral blood-derived DC were treated with
purified UV-inactivated HHV-6 virions overnight and then matured
with IFN- and LPS or left immature; mock-treated DC were exposed
to uninfected culture medium under the same conditions. A total of
105 allogeneic T cells were incubated with various numbers of either
immature (A) or mature (B) DC. Five days later, the cells were incu-
bated with radiolabeled thymidine and then were harvested and ana-
lyzed. Representative data (means
 SD for triplicate wells) for one of
three donors tested are shown.
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addition, antibody-mediated blocking experiments with APC
are complicated by the documented effects of Fc-receptor
ligation, which is per se sufficient to cause IL-12 downmodu-
lation (28). Regardless of these technical hurdles, the shared
use of CD46 by measles virus and HHV-6 is compatible with
the concept that binding to this receptor molecule, which is
emerging as a key link between innate and cognate immune
responses, does not simply represent a cell surface anchoring
maneuver, but rather is a key mechanism of microbial patho-
genesis. Understanding the fine molecular mechanisms of
HHV-6-mediated DC dysregulation may be useful for devising
novel therapeutic approaches to specifically counteract the im-
munosuppressive effects of microorganisms that engage the
CD46 receptor.
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